Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A

SSSE:600488
4.51
CNY
-0.10
(-2.17%)
0.07EPS
155.50P/E
7.30BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.6
1.44
1.46
1.56
1.81
2.22
3.04
2.84
3.47
3.33
3.46
2.94
2.68
2.34
Basic EPS, GAAP
0.06
0.09
0.08
0.09
0.12
0.13
0.15
0.03
0.04
0.03
0.11
0.12
0.06
0.04
Free Cash Flow per Basic Share
-0.24
0.17
0.09
-0.02
-0.12
-0.03
0.02
-0.1
-0.05
0.41
0.59
0.45
0.07
- -
Dividend per Share
0.04
0.04
0.04
0.04
0.03
0.07
0.1
0.07
0.05
0.05
0.04
0.11
0.12
0.11
Book Value per Share
2.4
2.47
2.53
2.88
2.49
2.67
2.76
2.72
2.72
2.71
2.7
2.8
2.78
2.77
Tangible Book Value per Share
2.37
2.44
2.49
2.74
2.35
2.54
2.57
2.49
2.41
2.32
2.27
2.31
2.31
2.31
Basic Weighted Avg Shares
927
962
960
1,086
1,091
1,092
1,093
1,096
1,082
1,106
1,094
1,094
1,086
1,086
Sales/Revenue/Turnover
1,481
1,389
1,405
1,689
1,972
2,427
3,327
3,117
3,749
3,689
3,783
3,215
2,908
2,541
Operating Margin (%)
4.78
5.77
5.45
8.69
11.04
12.35
11.28
7.16
6.38
6.69
6.46
9.8
10.38
7.94
Depreciation Expense
69
69
70
95
99
126
162
184
209
257
271
297
296
- -
Net Income, GAAP
52
87
79
98
130
145
162
34
49
35
117
133
71
47
Effective Tax Rate (%)
8.84
12.83
9.4
11.77
14.13
15.27
26.31
28.3
27.1
- -
3.31
8.08
0.04
5.14
Profit Margin (%)
3.51
6.23
5.6
5.79
6.58
5.98
4.86
1.09
1.3
0.96
3.09
4.15
2.43
1.84
Working Capital
731
1,258
934
1,512
728
754
159
81
-141
80
168
589
1,029
587
LT Debt
- -
385
- -
385
- -
385
- -
403
368
459
277
425
535
124
Total Equity
2,326
2,395
2,449
3,424
3,129
3,363
3,768
3,773
3,817
3,754
3,753
3,886
3,895
3,857
Return on Invested Capital (%)
1.5
2.17
2.7
3.99
4.4
4.89
4.63
1.94
2.07
- -
3.3
4.52
4.17
- -
Return on Capital (%)
2.79
3.87
3.33
2.12
2.9
3.2
3.07
0.33
0.43
- -
2.17
1.87
0.87
- -
Return on Common Equity (%)
2.39
3.7
3.28
3.76
4.73
5.15
5.46
1.13
1.63
1.19
3.95
4.44
2.32
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
127
529
518
LT Borrowings
535
124
103
LT Finance Leases
24
22
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,092
1,092
1,092
Market Capitalization
5,721
5,274
7,305

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,083
2,253
2,005
Cash, Cash Equivalents & STI
703
856
719
Accounts Receivable, Net
524
592
670
Inventories
606
592
507
Total Current Liabilities
1,004
1,600
1,418
Payables & Accruals
- -
- -
- -
ST Debt
127
529
518
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.41%
0.65%
0.23%
Free Cash Flow
-152.62%
-210.43%
-83.61%
Net Income, GAAP
21.47%
42.69%
-47.12%
Sales/Revenue/Turnover
8.75%
-0.67%
-9.56%
Total Cash Common Dividend
25.18%
23.18%
2.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
864
937
771
643
3,215
2025
786
803
- -
676
2,908
2026
608
705
551
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.08
0.04
-0.05
0.12
2025
0.05
-0.01
- -
- -
0.06
2026
0.01
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.09
0.04
-0.03
0.11
2025
- -
0.1
- -
- -
0.12
2026
- -
0.04
0.07
- -
- -

Company Description

CEO
Shu Xiang Li
Full Time Employees
2,731
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 221 Huanghai Road Tianjin TI China 300457
IPO Date
Jun 18, 2001
Website
tjpcty.com
Business
Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SS) engages in the research, development, production and sales of corticosteroids and amino acid active pharmaceutical ingredients (APIs) and finished dosage forms; its core products include corticosteroid APIs such as dexamethasone, prednisone, methylprednisolone and betamethasone series, as well as amino acid APIs like glycine, L-aspartic acid, L-glutamic acid, L-isoleucine, L-leucine and L-lysine acetate; dosage forms encompass injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, tablets, infusions and eye drops. The company operates production bases in Tianjin Binhai New Area, Xiangyang in Hubei Province and Yong Guang in Hebei Province, exporting to the United States, Southeast Asia, Europe, South America, Africa and other international markets; it serves hospitals, clinics and pharmacies with products for chronic and acute care in therapeutic areas including emergency rescue drugs, steroid hormones and biologics. Founded in 1939 and headquartered at No. 109, Bawei Road, Hedong District, Tianjin, China, the company functions as a subsidiary of Tianjin Pharmaceutical Group Co., Ltd. and maintains a workforce of approximately 2,884 employees with advanced quality systems including FDA certification for select sterile steroid hormone preparations. Recent developments include the establishment of an Innovation Research Institute in 2024 to advance innovative drug design, discovery and incubation, with early-stage projects like JYSW003 targeting psoriasis showing promising efficacy; the company reports eight new product approvals, 13 consistency evaluations and five FDA-certified products in recent years, alongside ongoing international cooperation such as with Pfizer. For the nine months ended September 30, 2025, it posted sales of CNY 2.23 billion and net income of CNY 69.54 million, reflecting strategic focus on product pipeline diversification, CDMO capabilities and high-value therapeutics.